Amicus Therapeutics FOLD
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Amicus Therapeutics (FOLD) Core Market Data and Business Metrics
Latest Closing Price
$7.99Price-Earnings Ratio
-23.50Total Outstanding Shares
307.24 Million SharesDividend
No dividendSIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
47 Hulfish Street, Princeton, NJ, 08542
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 2,344,617 Shares | 7.44 | 3/14/2025 | 17,454,472 Shares |
| 2,842,880 Shares | 5.47 | 2/28/2025 | 15,554,264 Shares |
| 2,133,211 Shares | 6.91 | 2/14/2025 | 14,736,437 Shares |
| 1,784,059 Shares | 9.72 | 1/31/2025 | 17,335,347 Shares |
| 2,582,113 Shares | 7.06 | 1/15/2025 | 18,230,381 Shares |
| 2,020,580 Shares | 9.58 | 12/31/2024 | 19,356,553 Shares |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Exchange Gains/Losses | $-11.04 Million |
| Net Cash Flow, Continuing | $-18.41 Million |
| Net Cash Flow From Financing Activities | $12.23 Million |
| Net Cash Flow From Investing Activities, Continuing | $-4.13 Million |
| Net Cash Flow From Financing Activities, Continuing | $12.23 Million |
| Net Cash Flow | $-29.45 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Income/Loss From Continuing Operations After Tax | $-104.69 Million |
| Income/Loss From Continuing Operations Before Tax | $-68.35 Million |
| Other Operating Expenses | $132.08 Million |
| Gross Profit | $444.24 Million |
| Income Tax Expense/Benefit | $36.34 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-72.95 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-72.95 Million |
| Other Comprehensive Income/Loss | $31.74 Million |
| Other Comprehensive Income/Loss Attributable To Parent | $31.74 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Current Liabilities | $158.14 Million |
| Noncurrent Assets | $288.08 Million |
| Fixed Assets | $30.44 Million |
| Other Current Assets | $383.14 Million |
| Noncurrent Liabilities | $449.59 Million |
| Intangible Assets | $18.03 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||